UK markets closed

Oxford BioMedica plc (OXB.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
323.50-2.00 (-0.61%)
At close: 04:35PM BST

Oxford BioMedica plc

Windrush Court
Transport Way
Oxford OX4 6LT
United Kingdom
44 1865 783 000

Full-time employees714

Key executives

NameTitlePayExercisedYear born
Mr. Thierry CournezCOO & Oxford Site HeadN/AN/AN/A
Mr. Matthew TreagusChief Information OfficerN/AN/AN/A
Sophia BolhassanHead of Investor RelationsN/AN/AN/A
Ms. Natalie Louise WalterGeneral Counsel & Company SecretaryN/AN/A1973
Ms. Lisa JamesChief People OfficerN/AN/AN/A
Dr. Kyriacos Mitrophanous Ph.D.Chief Innovation OfficerN/AN/AN/A
Ms. Kati HudsonHead of Intellectual Property and ContractsN/AN/AN/A
Dr. Sebastien RibaultChief Commercial OfficerN/AN/AN/A
Mr. Mark CaswellSite Head of US OperationsN/AN/AN/A
Ms. Stephanie ColloudSite Head & GM of France OperationsN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Corporate governance

Oxford BioMedica plc’s ISS governance QualityScore as of 1 June 2024 is 9. The pillar scores are Audit: 5; Board: 6; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.